Teaching Investors How To Turn Pennies Into Dollars TM

Advertising    Contact Us
Welcome, Guest Login / Sign-Up
Navigation menu

Featured Link


Add Us to favorites

Click Here Now!
or hit CRL+D


Search Web Site


American Company Spotlight


Medical Marijuana Inc. Website: Click Here

Information As Of June 4, 2012

Exchange: Pink Sheets Market Cap: 23.5 Million
Outstanding Shares: 559 Million 52 Low / High: $0.011 / $0.124

Price June 4, 2012: $0.042

MJNA Recent Stock Quote and News: Click Here

"In the latest quarter, MJNA earned net income of approximately $1.21 million on gross revenues of $1.79 million for the quarter ended March 31, 2012, an increase of more than 400% percent quarter-over-quarter when compared to revenue of $430,000 for the quarter ended December 31, 2011 and an accumulative more than 12,000% increase compared to the 2011 quarter."


The Company's mission is to be the premier cannabis and hemp industry innovator, leveraging their team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. The Company strives to create awareness within their industry, develop environmentally friendly, economically sustainable businesses, while increasing shareholder value. Medical Marijuana Inc. does not grow, sell or distribute any substances that violate United States Law or the controlled substance act.

Investment Highlights

  • Ready to Roll Industry. 17 U.S. states have now approved the use of medical marijuana with 11 more having pending legislation which could open market opportunities across more than half of the country for well-positioned leaders in the industry.
  • Massive Market Potential. The U.S. marijuana market alone is estimated by some analysts to be in excess of $110 billion. Medical marijuana is growing its footprint with consulting firm See Change Strategy LLC saying in a recent report that national medical-marijuana sales of $1.7 billion in 2011 could grow to $8.9 billion in five years.
  • Broad Product Portfolio. Medical Marijuana, Inc. provides a wide array of products, including medications that take the “stoned” component out of medical marijuana by focusing on the use of a THC-free cannabidiol, or CBD. The company provides over 50 proprietary and patented cannabinoid “delivery methods” that are more “socially and medically acceptable” than smoking.
  • Family of Companies. In a few, short years, Medical Marijuana Inc. has built a portfolio of companies to help broaden its industry footprint. Those companies include Phytosphere, HempMeds, Wellness Managed Services and Dixie Elixirs & Edibles, one of the largest THC-infused product makers in Colorado.
  • Anticipated Growth. The recent acquisition of Wellness Managed Services accounts will generate estimated annual revenues of $1.7 million and the acquisition of Dixie Elixirs & Edibles brand could generate millions more in revenue for MJNA immediately.
  • Financing Arranged. Funding is in place as the company secured $4 million in non-dilution, non-recourse finance for the acquisition and development of strategic acquisitions.


Many stocks are cyclic by nature. Mining stocks and biotechnology stocks generally make a move upward as milestone dates approach in anticipation of positive reports from the company. Other stocks move in groups based on industry news, whether it specifically pertains to the company or not. News from China on solar panels can be a driver for U.S. solar plays. Favorable words from Washington D.C. on stem cell research can send regenerative medicine companies soaring. To go into the theme of this profile, Medical marijuana stocks have been gradually gaining recognition over the last couple years as more and more states enact laws allowing medicinal use of cannabis. From a calendar standpoint, now is the time to start taking a look at the few public companies that are focused on medical marijuana because election time is drawing near in the U.S. and that could fuel a rise in stock prices as people hope for new laws to come from new politicians looking to appease constituents.

The debate over legalizing pot has been going on for decades with medical uses for marijuana estimated to go back more than 12,000 years. The industry began to earn true recognition in February of 1997 when the National Institutes of Health (NIH) released a report detailing the possible medical uses for marijuana and most productive avenues for research. The report highlighted several areas that marijuana is beneficial, including stimulating appetite and alleviation of cachexia, nausea control associated with chemotherapy, decreasing intraocular pressure, analgesia uses and control of neurological and movement disorders.

Last Friday, Connecticut joined the ranks of others to bring the total to 17 states that have now passed laws legalizing medical marijuana with 11 more states having legislation pending. Unless people are focused on the industry, many will not recognize that it is possible that greater than 50 percent of the States could have laws allowing medical marijuana in the near term.

Connecticut’s Governor Dannel P. Malloy signed into law legislation allowing licensed physicians to certify an adult patient's use of marijuana for medical purposes, according to a statement from the governor's office. "For years, we've heard from so many patients with chronic diseases who undergo treatments like chemotherapy or radiation and are denied the palliative benefits that medical marijuana would provide," Governor Malloy said.

Medical marijuana is now cited for use for many debilitating diseases such as cancer, glaucoma, Human Immunodeficiency Virus (HIV), Acquired Immune Deficiency Syndrome (AIDS), Parkinson's disease, multiple sclerosis and epilepsy, to name just a few.

With more states adopting policies permitting the medical use of marijuana, the industry as a whole is quickly growing. In reality, the business is still only in its infancy since it didn’t even exist two decades ago. With that in mind, analysts are now looking for non-linear growth which should lead to a small explosion for small companies that are rapidly emerging as leaders in the space.

Consulting firm See Change Strategy LLC said in a recent report that national medical-marijuana sales of $1.7 billion in 2011 could grow to $8.9 billion in five years. California and Colorado account for 92 percent of the current market. California leads the nation, with sales of $1.3 billion, according to the report. These estimates, while robust, could be considered conservative given the fact that the marijuana industry in the United States is estimated by some at more than $110 billion currently.

An expert in the field, appropriately-named Medical Marijuana Inc. (OTCBB:MJNA) is focused on its mission to be the premier cannabis and hemp industry innovators, leveraging its team of professionals to source, evaluate and purchase value-added companies and products. MJNA provides a wide array of products, including medications that take the “stoned” component out of medical marijuana by focusing on the use of a THC-free cannabidiol, or CBD.

CBD’s are a class of diverse chemical compounds that activate cannabinoid receptors. These include the endocannabinoids (produced naturally in the body by humans and animals), the phytocannabinoids (produced by various plants), and synthetic CBD (produced chemically by man). The most acknowledged cannabinoid is the phytocannabinoid, tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis. It is notable, that THC-free cannabidiols are rising in popularity with research showing that they can provide an even greater therapeutic benefit than their THC-containing cousins. The marijuana compound offers some of the pain-relieving benefits of THC, without the psychoactive effects. Just as importantly, hemp-based CBDs are legal in the United States, meaning patients don't need to live in a state with MMJ laws and don't have to worry about the government knocking on their door.

The company’s products range from patented and proprietary based cannabinoid products, to whole plant or isolated high value extracts specifically manufactured and formulated for the pharmaceutical, nutraceutical and cosmeceutical industries. MJNA provides over 50 proprietary and patented cannabinoid “delivery methods” that are more “socially and medically acceptable” than smoking.

Medical Marijuana Inc.’s patented and proprietary technologies include the only pharmaceutical grade vertical Bio-Technology Company specializing in the standardization, production and extraction of medicinal cannabinoids.

In short order, Medical Marijuana Inc. has built a portfolio of companies to help broaden its industry footprint. Those companies include Phytosphere, HempMeds, Wellness Managed Services and Dixie Elixirs & Edibles, one of the largest THC-infused product makers in Colorado.

The family of companies embodies the MJNA business strategies by covering the full gamut of revenue-generating opportunities within the industry. Phytosphere, a cannabinoid biotechnology company, uses advanced plant growth technologies to save significant time and resources in the production of medical grade cannabis, extracts and compounds. HempMeds Rx is a phyto medical company specializing in the production, development and sales of hemp-based compounds for the pharmaceutical, nutraceutical and supplement industries. Wellness Managed Services capitalizes, manages, acquires and develops retail stores and medical clinics involved in the medical hemp and alternative medicine fields. Accounts are currently being acquired in North America with plans for expansion into Europe and Asia in early 2013.

MJNA may have hit a home run by paying $1.45 million in May to purchase Dixie Elixirs & Edibles’ portfolio of Intellectual Properties, including formulas and recipes. Dixie sells a full range of goods through six unique hemp based product lines. The company formulates, develops, produces, licenses and sells its products both in the U.S. and abroad. Products consist of cannabis-infused medications available in drinks, food products (such as truffles, lozenges, rice treats and chocolate rolls), capsules and botanicals; giving consumers a wide array of options in how they medicate.

Dixie sells products to 450 of Colorado's 593 medical-marijuana dispensaries. MJNA is looking to take the dominance of Dixie pan-America via a licensing deal that created a new company, Red Dice Holdings, that will see the branded products sold in other states by the end of 2012. All tallied, Dixie’s products can be found in more than 600 stores presently, with plans for substantial expansion in the short-term.

Financially speaking, the company is positioned to boom. According to their latest quarterly reports in May, MJNA earned net income of approximately $1.21 million on gross revenues of $1.79 million for the quarter ended March 31, 2012. This represents a gross revenue increase of 400 plus percent quarter-over-quarter when compared to revenue of $430,000 for the quarter ended December 31, 2011 and an accumulative 12,000 plus percent increase in revenue since the same quarter last year. Operating expenses were approximately $580,000 for the quarter.

While those gains are very impressive, the real potential of the company appears ready to start to be showcased as it acquired two additional Wellness Managed Services accounts which will generate estimated annual revenues of $1.7 million and closed the acquisition of Dixie Elixirs & Edibles brand, which could generate millions more in revenue for MJNA immediately.

Funding is in place as the company secured $4 million in non-dilution, non-recourse finance for the acquisition and development of strategic acquisitions. In a commitment to shareholder value, 14.6 million shares were retired in the latest quarter.

Michael Llamas, President of Medical Marijuana, Inc. commented, "We have spent this last year essentially getting our house in order by clarifying the growth strategy and systematically identifying, acquiring and growing early stage companies across the spectrum of the MMJ industry from product development to retail sales. As witnessed by our strong quarter-over-quarter and year-over-year growth, there is tremendous opportunity in this industry.”

Technically speaking, the MJNA chart has some solid support at 4 cents with additional support at 3.5 cents in both a static fashion from the candlesticks as well as the dynamic support of the 200 day simple moving average. That area held consistently as support throughout May and technical traders may be employing the old adage of “buy on support” with the stock closing at $0.042 today. A move from here and the chart will be making a higher low and the start to a new upward trend. To the north side, there is little resistance until a 20 percent move to the 5 cent mark. Savvy traders will be watching for volume to increase on a run at that level because the next resistance is 20 percent further down the road at 6 cents. A break of that and the chart could potentially make a move towards 52-week highs at 11 cents.

The price per share is pulling back from its recent run-up to 6.5 cents, but volume is diminishing, which could signal that the profit taking from the move is coming to an end. The Moving Average Convergence/Divergence (MACD) still has the potential to rotate and make a higher low right around zero, which would be a bullish indication for the chart showing that the trend is going to shift back towards bullishness. Other indicators that measure momentum, such as the Relative Strength Index (RSI) and the Full Stochastics are approaching oversold levels, lending further credence to the potential of a bounce from current levels. A move back through the 50 mark by the RSI indicates bullish momentum coming back into the play. With support being show in the chart around $0.035 to $0.04, we encourage investors to consider stop-losses around those levels depending on their risk tolerance to protect against downside risk. As we always mention at this point, these are merely the interpretations of We encourage all investors to do their own due diligence and consult with a financial advisor prior to making any investment decisions.

With a full team of industry professionals in management positions and more than 20 employees, Medical Marijuana, Inc. is locked and loaded to amplify their strategic initiatives that they have methodically assembled over the last couple years. With a market cap of only $23 million, the potential upside to the company in an industry that is set for massive growth is deserved of a much closer look. Factor-in elections coming in the states as a time that could lead to a run in share value and it could be a perfect storm brewing for this company. It is for these reasons that we encourage our members to begin their due diligence on Medical Marijuana, Inc. (OTCBB:MJNA) and promptly add it to their watchlists.

Recent News and Press Releases

Medical Marijuana Inc. Portfolio Company, Red Dice Holdings, Sees Continued Brand Recognition With CO-based Dixie Elixirs
PR Newswire (Fri, Jun 1)

Medical Marijuana Business Daily Article Highlights Medical Marijuana, Inc. Line of Hemp-Based, THC-Free Products and the Growing Promise of Cannabidiol
PR Newswire (Fri, Jun 1)

A New Audio Interview with Vincent "Tripp" Keber President and CEO of Red Dice Holdings, LLC, a Medical Marijuana, Inc. Subsidiary, is now at
PR Newswire (Wed, May 30)

Medical Marijuana, Inc. Appoints Vincent "Tripp" Keber to Board of Directors
PR Newswire (Wed, May 30)

SmallCapVoice Interview with Medical Marijuana, Inc. (Pink Sheets: MJNA) (05/21/2012)
PR Newswire (Wed, May 23)

Medical Marijuana Inc. (MJNA) Corporate Update on Industry Company Services and Future Development. First Audio-Webcast Interview With in Quarterly Series
PR Newswire (Tue, May 22)

Medical Marijuana, Inc. Submits Updated 15c2-11 Filing
PR Newswire (Thu, May 17)

Medical Marijuana, Inc. Announces First Quarter 2012 Results
PR Newswire (Tue, May 15)

Dixie Elixirs & Edibles and PhytoSPHERE Systems, Portfolio Companies of Medical Marijuana, Inc, Grow Relationship with New Licensing Agreement
PR Newswire (Thu, May 10)


The Medical Marijuana Inc. (MJNA) team is made up of a diverse group of highly skilled professionals in their respected fields. Each individual who makes up the corporate structure of MJNA plays an integral part of the company’s day to day operation and overall success. MJNA believes for a company to not merely succeed but thrive in any economic and political environment you must first have the right people on the team, make sure they are in the right position, and allow them to operate with integrity and an entrepreneurial spirit.

The MJNA executive team work with industry and world authorities on cannabinoid based science and technologies to source, evaluate, acquire and develop value added companies and products. Each of the entities that make Medical Marijuana Inc.’s structure has a clearly defined purpose as it relates to an individual market, consumer or partner need. By utilizing these different facets, MJNA is able to provide an unparalleled platform of businesses that are unique among industry competitors. The professionals at MJNA are dedicated to “keeping it simple”. In an industry that has ever changing economic, political and scientific climate, its MJNA’s team’s ability to do just that that sets it apart.

Michael Llamas - President and Director

Robert Plomgren - Chief Financial Officer

Michelle Sides - Chief Operating Officer, Chairman

David Darlington - President, PhytoSHERE Systems, Vice Chairman

Tripp Keber - President, RDH Licensing

Babak R. Ghalili - Medical Director


Company Headquarters:

Medical Marijuana Inc.

2665 Ariane Drive Suite 207
San Diego, CA 92117
Toll Free: 888 OTC-MJNA
Toll Free: 888-682-6562
Facsimile: 888 651-0349

Investor Relations Contact:

SmallCapVoice.Com, Inc.

Stuart T. Smith
Phone: 512 267-2430
Facsimile: 512 267 2530


This report includes forward-looking statements that reflect Medical Marijuana Inc. current expectations about its future results, performance, prospects and opportunities. Medical Marijuana Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Medical Marijuana Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

Disclaimer feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Medical Marijuana Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2012 All rights reserved. is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the web site. has been compensated six thousand dollars and two thousand five hundred dollars worth of services by a non-affiliated third-party, Inc. for its efforts in presenting the MJNA profile on its web site and distributing it to its database of subscribers as well as other services. may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.


We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: and/or the National Association of Securities Dealers (NASD) at: Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

 © 1999 - 2013. is a web publishing venture produced by Media, Inc.